PT  - JOURNAL ARTICLE
AU  - ISHIKAWA, TAKASHI
AU  - SHIMIZU, SATORU
AU  - KATAYAMA, KIYOFUMI
AU  - CHISHIMA, TAKASHI
AU  - HAMAGUCHI, YOHEI
AU  - DOI, TAKAKO
AU  - TANABE, MIKIKO
AU  - KASAHARA, AKIO
AU  - YAMAGUCHI, NAOTAKA
AU  - NARUI, KAZUTAKA
AU  - OHTA, IKUKO
AU  - MATSUMOTO, CHIZURU
AU  - SHIMIZU, DAISUKE
AU  - KITO, AYAKO
AU  - SUDA, TAKASHI
AU  - INABA, MASAAKI
AU  - ASAGA, TARO
AU  - MOMIYAMA, NOBUYOSHI
AU  - ICHIKAWA, YASUSHI
AU  - YOSHIMOTO, MASATAKA
AU  - MORITA, SATOSHI
AU  - SHIMADA, HIROSHI
TI  - Feasibility of AC/EC Followed by Weekly Paclitaxel in Node-positive Breast Cancer in Japan
DP  - 2009 May 01
TA  - Anticancer Research
PG  - 1515--1520
VI  - 29
IP  - 5
4099  - http://ar.iiarjournals.org/content/29/5/1515.short
4100  - http://ar.iiarjournals.org/content/29/5/1515.full
SO  - Anticancer Res2009 May 01; 29
AB  - The feasibility and efficacy of adriamycin or epirubicin in combination with cyclophosphamide followed by weekly paclitaxel (AC/EC-weekly PAC) as adjuvant chemotherapy for breast cancer was investigated. Patients and Methods: Node-positive breast cancer was treated with AC/ EC-weekly PAC, namely AC at 60/600 mg/m2 or EC at 90/600 mg/m2 ×4 at three-week intervals, followed by weekly PAC (80 mg/m2) ×12, namely four cycles of single weekly administration for three weeks followed by a one-week rest (3×4 PAC) or single weekly administration for 12 consecutive weeks (12 PAC). Results: One hundred and three of 109 consecutive patients enrolled were analyzed, of whom 96 (93.2%) completed the regimen. Grade 3/4 neutropenia occurred in 52.4% receiving AC/EC, and 10.9% of 55 receiving 12 PAC but only 2.1% of 48 receiving 3×4 PAC. Neuropathy disorders occurred in more than half receiving PAC, which did not improve after one-week rest in 3×4 PAC. Conclusion: AC/EC-weekly PAC is feasible and without serious complications.